Three Rivers expands rights to Infergen
This article was originally published in Scrip
Executive Summary
Three Rivers Pharmaceuticals has gained more commercial rights to Amgen's hepatitis C drug Infergen ((interferon alfacon-1). The definitive licence agreement signed with Amgen will give Three Rivers commercial rights to the drug in all markets except Japan and it will obtain commercial rights in China from March 31st, 2009. The company currently has commercial rights to Infergen in the US and Canada which it bought from Valeant Pharmaceuticals late last year (Scrip Online, December 21st, 2007). Three Rivers will seek marketing partners to help commercialise Infergen outside the US.